年轻乳腺癌幸存者中抗癌治疗暴露不同导致长期抗苗勒管激素模式存在差异
本研究利用行政数据比较了乳腺癌确诊后6年内抗癌治疗暴露与无癌女性的抗苗勒管激素(AMH)模式。233例乳腺癌患者贡献278个AMH值,2777名匹配无癌女性贡献2780个AMH值。无癌女性和未化疗乳腺癌幸存者的AMH随时间线性下降;接受环磷酰胺类或非环磷酰胺类化疗者则呈先降后升再平台再降的非线性模式。
要点
- 无癌女性和未化疗乳腺癌幸存者的AMH随时间线性下降。
- 接受环磷酰胺类或非环磷酰胺类化疗者AMH呈先降后升再平台再降的非线性模式。
- 行政数据支持非环磷酰胺类化疗对乳腺癌症患者具有卵巢毒性。
核心结论
- 在乳腺癌幸存者中,来自行政数据的AMH水平支持非环磷酰胺类化疗对乳腺癌的卵巢毒性,并有效描绘了卵巢储备变化的时间与持续时间,以反映剩余生殖寿命。
研究设计与样本
- 采用横断面设计,将2005-2019年间15-39岁发生乳腺癌的患者与OptumLabs Data Warehouse中无癌女性按1:10匹配。
- 比较环磷酰胺类化疗、非环磷酰胺类化疗、未化疗和无乳腺癌四组的模型化AMH模式。
- 共233例乳腺癌患者(平均年龄34岁,标准差3.7岁)贡献278个AMH值,中位随访2年(范围0-6.7年);2777名匹配无癌女性贡献2780个AMH值。
主要发现
- 乳腺癌患者中52%接受环磷酰胺类化疗,17%接受非环磷酰胺类化疗(其中80%为铂类),31%未接受化疗。
- 四组间AMH水平模式存在差异。
- 无癌女性和未化疗乳腺癌幸存者的AMH随时间线性下降。
- 接受环磷酰胺类或非环磷酰胺类化疗者呈现非线性AMH模式:化疗期间初始下降,随后2-4年上升,之后1-2年平台期,再下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare antimüllerian hormone (AMH) patterns by cancer status and treatment exposures across 6 years after incident breast cancer using administrative data. DESIGN: In a cross-sectional design, AMH levels in patients who developed incident breast cancer between ages 15-39 years during 2005-2019 were matched 1:10 to levels in females without cancer in the OptumLabs Data Warehouse. Modeled AMH patterns were compared among cyclophosphamide-based chemotherapy, non-cyclophosphamide-based chemotherapy, no chemotherapy, and no breast cancer groups. SETTING: Commercially insured females in the United States. PATIENT(S): Females with and without breast cancer. EXPOSURE(S): Breast cancer, cyclophosphamide- and non-cyclophosphamide-based chemotherapy. MAIN OUTCOME MEASURE(S): AMH levels. RESULT(S): A total of 233 patients with breast cancer (mean age, 34 years; standard deviation, 3.7 years) contributed 278 AMH levels over a median of 2 years (range, 0-6.7 years) after diagnosis; 52% received cyclophosphamide-based chemotherapy, 17% received non-cyclophosphamide-based chemotherapy (80% platinum-based), and 31% received no chemotherapy. A total of 2,777 matched females without cancer contributed 2,780 AMH levels. The pattern of AMH levels differed among the 4 groups. Among females without cancer and breast cancer survivors who did not undergo chemotherapy, AMH declined linearly over time. In contrast, among those who received cyclophosphamide-based and noncyclophosphamide-based chemotherapy, a nonlinear pattern of AMH level of initial fall during chemotherapy, followed by an increase over 2-4 years, and then by a plateau over 1-2 years before a decline was observed. CONCLUSION(S): In breast cancer survivors, AMH levels from administrative data supported ovarian toxicity of non-cyclophosphamide-based chemotherapy in breast cancer and efficiently depicted the timing and duration of changes in ovarian reserve to reflect the residual reproductive lifespan.
引用
- Zhou B, Kwan B, Desai MJ, et al. Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors. Fertil Steril. 2022. PMID: 35216831. doi:10.1016/j.fertnstert.2022.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。